We publish the CarelonRx Drug and Biologic Pipeline Update each quarter to keep you informed about upcoming Food and Drug Administration (FDA) approvals. This newsletter analyzes drugs and biologics in development and other clinical topics of interest.
Download the PDF to learn about:
- Three agents with anticipated approvals in 2025 for bronchiectasis, spinal muscular atrophy (SMA), and mucopolysaccharidosis II (MPS II).
- Other significant treatments expected in the next few years, including gene therapies and biosimilars in the pipeline.
- The use of artificial intelligence to support regulatory decision making for drug and biologic products.
- Potential future Keytruda® indications, as well as an overview of recent Kidney Disease: Improving Global Outcomes (KDIGO) guidelines.
Information presented is from various publicly available resources and for informational purposes only. This document does not provide information on confidential CarelonRx proprietary clinical programs or management strategies.
You may also be interested in:
Q2 2025 CarelonRx DrugInsights Update
Regulatory and Legislative Activity Update Q2 2025
